Results 11 to 20 of about 182,500 (270)
Pembrolizumab (Keytruda) [PDF]
The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells. PD1 expression is an important mechanism contributing to the exhausted effector T-cell phenotype.
Tse, EWC +4 more
openaire +5 more sources
Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report
Background Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of several cancers. Pembrolizumab is an anti-programmed cell death-1 (anti-PD-1) monoclonal antibody that is approved for the treatment of metastatic non-small ...
Zhi Yang +4 more
doaj +2 more sources
Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review [PDF]
As pembrolizumab has been widely used in the immunotherapy of various solid tumors such as melanoma and lung cancer, reports of pembrolizumab-related adverse drug events have gradually attracted attention; however, cases of pembrolizumab-induced ...
Shujun Sun +3 more
doaj +2 more sources
: Favezelimab plus pembrolizumab had promising efficacy in anti–programmed cell death protein 1 (PD-1)–refractory classical Hodgkin lymphoma in MK-4280-003; however, the contribution of favezelimab was unclear. Here, we assessed the relative contribution
Philippe Armand +8 more
doaj +2 more sources
Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
Background Pembrolizumab as immunotherapy is increasingly used in adjuvant, neoadjuvant, and standalone therapy and has been described as safe. We share an experience of lung erosion post-thoracic surgery with the use of adjuvant pembrolizumab.
Lowell Leow +3 more
doaj +2 more sources
89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs [PDF]
Background To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential.
Annelies Jorritsma-Smit +5 more
doaj +2 more sources
Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab [PDF]
Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab.
Sijan Basnet +2 more
doaj +2 more sources
Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients.
Tan Chongqing +15 more
doaj +1 more source
AbstractThe current approval indications for pembrolizumab are complex, reflecting the inclusion criteria of numerous clinical trials that led to approvals. Here we argue that allowing the use of pembrolizumab to any advanced solid tumor in any tumor type in any line of therapy for a fixed duration may be preferable to the current assortment of ...
Kim, Myung S, Prasad, Vinay
openaire +4 more sources
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma [PDF]
PURPOSEThe combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study.
Gansert, J. +28 more
core +3 more sources

